Role of regulatory T cell in the pathogenesis of inflammatory bowel disease

Akiko Yamada, Rieko Arakaki, Masako Saito, Takaaki Tsunematsu, Yasusei Kudo, Naozumi Ishimaru

Abstract

Regulatory T (T\text{reg}) cells play key roles in various immune responses. For example, T\text{reg} cells contribute to the complex pathogenesis of inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis during onset or development of that disease. Many animal models of IBD have been used to investigate factors such as pathogenic cytokines, pathogenic bacteria, and T-cell functions, including those of T\text{reg} cells. In addition, analyses of patients with IBD facilitate our understanding of the precise mechanism of IBD. This review article focuses on the role of T\text{reg} cells and outlines the pathogenesis and therapeutic strategies of IBD based on previous reports.

Key words: Inflammatory bowel disease; Regulatory T cell; Animal model; Therapy

© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: We review the types and functions of regulatory CD4\textsuperscript{+} T cells (T\text{reg} cells) and describe their roles in the pathologies of the inflammatory bowel diseases, i.e., Crohn's disease and ulcerative colitis. We have paid particular attention to the use of animal models and human studies to elucidate the mechanisms by which T\text{reg} cells influence these diseases and have provided an overview of the potential uses of these cells in therapeutic strategies.
INTRODUCTION

Inflammatory bowel disease (IBD) is a term that encompasses two major forms of chronic inflammatory intestinal disorders: Crohn’s disease (CD) and ulcerative colitis (UC) [1-3]. Both of these chronic inflammatory diseases feature a typical time of onset during young adulthood and a lifelong course characterized by periods of remission and relapse [4,5]. The pathogenesis of IBD is well known to be complex because of various immunological, environmental, host genetic, and bacterial factors, and the complicated regulatory mechanisms associated with mucosal immunity can also influence the onset or development of IBD [6-8]. Many reports of various animal models of IBD have revealed cellular or molecular mechanisms of IBD and the recent use of anticytokine agents, such as anti-tumor necrosis factor-α (TNF-α), interleukin (IL)-6R, or IL-13 antibodies, has achieved progress in healing mucosal damage associated with IBD [9,10].

Regulatory T (T_{reg}) cells are known to play a key role in the pathogenesis of IBD, as well as in other autoimmune disorders or allergies [11-15]. Considerable evidence supports the notion that an altered balance between Foxp3^{+}CD4^{+} T_{reg} cells and T effector cells in the intestinal microenvironment might contribute to the pathogenesis of IBD [12,15]. The ability to control inflammatory lesions with transferred T_{reg} cells has been demonstrated in several IBD models [16,17]. On the other hand, patients with IBD have been found to harbor significantly reduced numbers of peripheral T_{reg} cells or increased serum level of soluble IL-2Rα [18,19]. Therefore, it is possible that a novel therapy involving T_{reg} cells might effectively treat IBD.

This review will focus on the functions of T_{reg} cells in controlling peripheral immune tolerance within the context of mucosal immunity and will explain the molecular pathogenesis of IBD and possible therapeutic strategies involving T_{reg} cells.

PATHOGENESIS OF IBD

The functions of mucosal immune system depend on the presence of intestinal flora [20]. In the intestinal epithelium, four cell types are found, including columnar cells, goblet cells, endocrine cells, and leukocytes to rest on a continuous basement lamina [21]. In addition, the immune cells in the lamina propria (LP), the leukocytes also involve various immune cells, such as the unique immune cell types that exist in gut- or mucosa-associated lymphoid tissues such as Peyer’s patches, mesenteric lymph nodes, and isolated lymphoid follicles. Balanced mucosal immunity in the gut is important for both immune homeostasis and defense [22-24]. Intestinal immunity is maintained by the proportions of immune cells such as dendritic cells (DCs), macrophages, effector CD4^{+} or CD8^{+} T cells, and T_{reg} cells.

Previously reported genome-wide association studies have identified more than 100 distinct loci that confer risk or protection from IBD development although a substantial proportion of these loci are common to both diseases [6]. Many IBD-associated pathways are known to exert heterogeneous effects upon activation in different cell types, and the combination of these cellular outcomes might affect disease manifestation [8,25]. IBD-associated loci can be broadly categorized into several critical pathways such as the innate immune response, intestinal barrier, microbial defense, reactive oxygen, and antimicrobial activity [26]. For example, in humans, nucleotide-binding oligomerization domain-containing protein 2 (NOD2), which is encoded by the NOD2 gene on chromosome 16 plays an important role in the intestinal immune system where it recognizes bacterial peptides and stimulates immune reactions [27]. Mutations in NOD2 gene have been associated with CD [27]. Furthermore, NOD2^{+/-} mice are susceptible to and demonstrate excessive intestinal inflammation when compared with control mice [28]. Treatment with NOD2 ligands, including peptidoglycan or muramyl dipeptide has been shown to ameliorate 2,4,6-trinitrobenzenesulfonic acid (TNBS)- or dextran sulfate sodium (DSS)-driven colitis in normal mice [29,30]. Treatment with Lactobacillus peptidoglycan was shown to increase the number of CD103^{+}DCs and Foxp3^{+} T_{reg} cell in mesenteric lymph nodes and IL-10 expression in the colonic mucosa in a TNBS-driven model of colitis, suggesting that NOD2 activity in the intestinal mucosa potentiates a tolerogenic environment [30].

Homing or migration-associated receptors such as CD62L, C-C chemokine receptor (CCR)7, α4β7 integrin, α4β7 integrin, CCR4, CCR5, and CCR9 also contribute to the pathogenesis of IBD [21-27]. The expression of these receptors on T_{reg} cells plays a key role in the intestinal immunological homeostasis and defective expression of these receptors has been shown to induce IBD as a result of the deficient migration of T_{reg} cells into the intestine. For example, a loss of CCR7 was found to block T_{reg} cell function in an experimental model of colitis [32].

ANIMAL MODELS OF IBD AND T_{reg} CELLS

Many animal models of IBD have been developed based on the various aspects in the pathogenesis or mechanisms of IBD [16,38]. Mice have been widely used to examine the contribution of bacteria and specific bacterial factors to the pathogenesis of IBD [39]. Studies conducted in germ-free, specific pathogen-free, and gnotobiotic mice have suggested that defined or specific microbial flora plays a fundamental role in
the initiation and development of IBD [39-41]. Additional experimental colitis mouse models have been induced using chemical drugs such as DSS, TNBS, oxazolone, or acetic acid [9,42-46]. In addition, adoptive transfer models in which a T-cell deficient mouse strain is reconstituted with T<sub>reg</sub> cell-depleted naïve T cells from a congenic donor mouse have been widely used [16,38,47]. Additional genetic models, including gene knockout, transgenic, or mutant animals, have been utilized to understand the genetic and molecular pathogenesis of IBD [9,16,38]. As spontaneous models of IBD, several animal models mice and rats are known to understand the pathogenesis of IBD or investigate new therapeutic strategy for IBD [9,38].

**Bacteria-infected models**

Studies conducted in mouse models of IBD have indicated that the T<sub>reg</sub> cell compartment is particularly sensitive to microbiota changes [48]. T<sub>reg</sub> cells from germ-free mice are generally less suppressive and express lower level of Foxp3 than do T<sub>reg</sub> cells from normal mice [49-51]. The colons of germ-free mice harbor reduced number of T<sub>reg</sub> cells, although this population was shown to increase in response to a decrease in bacterial load following vancomycin treatment [52,53]. *Citrobacter rodentium*-infected mouse models have been the preferred infection models in acute intestinal inflammation [54]. Helicobacter-infected mice have been used to be a bacterial infection model in combination with the other model [55]. In addition, toll-like receptor 9 (TLR9)-deficient mice harbor increased numbers of T<sub>reg</sub> cells in the small intestine, suggesting that inflammatory signals from bacterial DNA play a role in inhibiting induced T<sub>reg</sub> cell differentiation or T<sub>reg</sub> cell proliferation [12,55].

**Gene-manipulated models**

*IL-2<sup>-/-</sup>*, *IL-2R<sup>-/-</sup>* and *IL-10<sup>-/-</sup>* mice are known IBD models in which reduced T<sub>reg</sub> cell number or dysfunction of T<sub>reg</sub> cells are observed [41,19,56-60]. In addition, innate or mucosal immunity-related gene-deficient mice, such as *NOD2<sup>+/–</sup>* and *NOD2<sup>-/-</sup>* myeloid differentiation primary response 88 (*MYD88*)<sup>-/-</sup>, nuclear factor-κB (*NF-κB*)<sup>-/-</sup>, cytokine-deficiency induced colitis susceptibility 1 (*CDCS1*)<sup>-/-</sup>, multidrug resistance gene 1a (*MDR1a*)<sup>–/–</sup>, and TLR5<sup>–/–</sup> mice, also reveal inflammatory lesions in the colon [52,61-70]. T-cell receptor (*TCR*)<sup>+/–</sup> mice are also known to be one of IBD models [61]. Overexpression of *TNF-α* and signal transducer and activator of transcription 4 (*STAT4*)<sup>–/–</sup> in mice results in the development of IBD-like lesions [16,71]. Moreover, there are various gene-manipulated models, in which epithelial barrier- and immune regulation-associated genes are manipulated by knockdown, knockin, conditional knockout, or transgenic mice (Table 1) [9,16,38,39,72-81]. Among them, a reduction of T<sub>reg</sub> cell number or impaired T<sub>reg</sub> cell function is observed in several models (Table 1) [9,16,38,39,72,77,78].

**Spontaneous models**

As one of spontaneous IBD models based on the pathogenic factor by T<sub>reg</sub> cells, senescence-accelerated mouse protein (SAMP1/YitFc (SAMP) mice are well known [83]. A functional abnormality in T<sub>reg</sub> cells in SAMP mice is observed [83]. C3H/HeJBir mice with high susceptibility to bacteria have been also used to be a model of IBD [84]. In addition, a monkey model, cotton-top tamarin, infected with *Campylobacter Jejuni* is known to be a spontaneous model of IBD [85]. Moreover, long-evans cinnamon (LEC) rat is a spontaneous IBD model based on T<sub>reg</sub> cell-associated pathogenicity [86]. The LEC rat was first described as a naturally occurring mutant with a defect in thymocyte development: specifically, T-cell differentiation is arrested at the transition from CD4<sup>+*/–</sup>CD8<sup>+</sup>* double positive to CD4<sup>+</sup>CD8<sup>+</sup>* single positive (SP), but not to CD4<sup>+</sup>CD8<sup>+</sup> SP, thymocytes [87]. Accordingly, in LEC rats, peripheral CD4<sup>+</sup> T cells did not function as Th cells in terms of antibody production against T-cell-dependent antigens, as well as in IL-2 production [87]. In addition, significantly reduced numbers of thymic and peripheral Foxp3<sup>–/–</sup> T<sub>reg</sub> cell and a defect in the suppressive activity of T<sub>reg</sub> cells were observed in these rats [86]. Interestingly, the proportion of T<sub>reg</sub> cells in the LP is significantly decreased in LEC rats when compared with control rats [86]. These findings suggest that the dysfunction in the T<sub>reg</sub> cell-controlled regulatory system may play a crucial role in the development of IBD.

**REGULATORY T CELL**

**Differentiation of T<sub>reg</sub> cells**

Forhead box P3 (Foxp3)-expressing T<sub>reg</sub> cells are a suppressive subset of CD4<sup>+</sup> T cells that control autoimmunity, allergy, infection, and tumors [11,88]. Natural T<sub>reg</sub> (nT<sub>reg</sub>) cells arise as a discrete and largely stable lineage in the thymus [89,90]. The nT<sub>reg</sub> subset exhibits a TCR repertoire that is distinct from those of Foxp3 conventional T cells and induced (iT<sub>reg</sub>) cells [91-94].

nT<sub>reg</sub> cells require IL-2 for the development and maintenance and were initially identified by their elevated expression of the high-affinity IL-2 receptor (CD25) [11]. Mice that lack the ability to conduct IL-2-mediated signaling following the injection of anti-IL-2 mAb or as a result of IL-2 or IL-2R gene knockout exhibit defects in the number and function of nT<sub>reg</sub> cells [95-98]. The most important finding in mice with deficient IL-2 signaling is the development of spontaneous autoimmune lesions, including IBD [96-98].

nT<sub>reg</sub> cells share phenotypic features with naïve and memory conventional T cells [95]. Most T<sub>reg</sub> cells in circulation and the lymphoid organs express CCR7 and the adhesion receptor CD62L, which direct their recirculation through lymphoid tissues; effector or activated T<sub>reg</sub> cells comprise a minor fraction of these [88,99]. Similar to activated conventional T cells, this T<sub>reg</sub> cell population exhibits phenotypes...
such as CD62L+CCR7+CD44lo killer cell lectin-like receptor subfamily G member 1 (KLRG1)+CD103+ or CD45RA+CD25+ is thought to have encountered antigens\(^{133,100-102}\). These cells exhibit enhanced migration through nonlymphoid tissues.

Tissue-resident T\(_{\text{reg}}\) cells can be found in non-lymphoid tissues, even under noninflammatory conditions\(^{89,103}\). Various tissues such as the skin, lungs, liver, salivary gland, lacrimal gland, intestinal mucosa, adipose tissue, and placenta are known to harbor substantial numbers of T\(_{\text{reg}}\) cells in both humans and mice\(^{14,104}\). For example, CCR7+Foxp3+ T\(_{\text{reg}}\) cells were found to reside in the salivary glands of healthy humans and mice whereas the number of CCR7+Foxp3+ T\(_{\text{reg}}\) cells was extremely decreased in the tissues from patients and model mice with Sjögren’s syndrome, an autoimmune disease that affects the exocrine glands such as the salivary and lacrimal glands\(^{104,105}\).

**Peripheral T\(_{\text{reg}}\) cells**

T\(_{\text{reg}}\) cells are generated from peripheral naïve conventional CD4\(^+\) T cells during the course of an immune response\(^{12}\). In healthy mice, most peripheral T\(_{\text{reg}}\) cells in the spleen and lymph nodes are thymus-derived nT\(_{\text{reg}}\) cells. By contrast, the iT\(_{\text{reg}}\) population resides in the intestinal LP and gut-associated lymphoid tissue (GALT)\(^{48,106}\). iT\(_{\text{reg}}\) cell generation involves naïve T-cell activation in the presence of transforming growth factor-\(\beta\) (TGF-\(\beta\)): in this setting, antigen exposure induces iT\(_{\text{reg}}\) cell differentiation\(^{107}\). iT\(_{\text{reg}}\) cells are particularly prevalent at mucosal surfaces where tolerance is induced against various antigens within the colonizing microbiota\(^{52,108}\). In addition, ingested food contains a plethora of antigens: in particular, food antigen feeding experiments identified a TGF-\(\beta\)1-producing CD4\(^+\) T cell population in the LP and GALT\(^{109}\). Immune responses to these dietary molecules can be actively suppressed by inducing oral tolerance\(^{110}\). Experiments with germ-free mice have suggested that bacterial commensals are essential for the development of normal numbers of colonic T\(_{\text{reg}}\) cells\(^{109}\). In the human microbiota, 17 clostridial strains that induce T\(_{\text{reg}}\) cell gut-homing and expansion by producing large amounts of short-chain fatty acids (SCFAs), which are bacterial breakdown products of plant-derived fibers were identified\(^{111,112}\). In particular, the SCFAs propionate, butyrate, and acetate can restore clonal T\(_{\text{reg}}\) cell numbers in germ-free or antibiotic-treated mice\(^{112}\).

Although the gastrointestinal tract harbors the largest reservoir of tissue-resident T\(_{\text{reg}}\) cells in the

---

**Table 1 Animal models of inflammatory bowel disease**

<table>
<thead>
<tr>
<th>Group</th>
<th>Model</th>
<th>Association</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemical drug-induced model</td>
<td>DSS</td>
<td>TNF-(\alpha), IL-17, reduced T(_{\text{reg}}) cells</td>
<td>[43]</td>
</tr>
<tr>
<td></td>
<td>TNBS</td>
<td>IL-12, IL-17, reduced T(_{\text{reg}}) cells</td>
<td>[44]</td>
</tr>
<tr>
<td></td>
<td>Ozaexolone</td>
<td>IL-4</td>
<td>[45]</td>
</tr>
<tr>
<td></td>
<td>Acetic acid (rat)</td>
<td>Myeloperoxidase</td>
<td>[46]</td>
</tr>
<tr>
<td>Adoptive transfer model</td>
<td>Naïve T cell→Rag+/−/SCID</td>
<td>Recovery by T(_{\text{reg}}) cell transfer</td>
<td>[16]</td>
</tr>
<tr>
<td>Bacteria-infected model</td>
<td>C. rodentium</td>
<td>Acute infection, IL-17</td>
<td>[54]</td>
</tr>
<tr>
<td></td>
<td>Helicobacter, etc.</td>
<td>Combined with the other models</td>
<td>[47]</td>
</tr>
<tr>
<td>Spontaneous model</td>
<td>SA/M/Yit/Fc</td>
<td>Dysfunction of T(_{\text{reg}}) cell</td>
<td>[83]</td>
</tr>
<tr>
<td></td>
<td>C3H/HeJ/Bir</td>
<td>Increased susceptibility to bacteria</td>
<td>[84]</td>
</tr>
<tr>
<td></td>
<td>Cotton-top Tamarin (monkey)</td>
<td>C. pijuni infection</td>
<td>[85]</td>
</tr>
<tr>
<td></td>
<td>LEC (rat)</td>
<td>Reduced T(_{\text{reg}}) cells</td>
<td>[86]</td>
</tr>
<tr>
<td></td>
<td>IL-2(^+)</td>
<td>Reduced T(_{\text{reg}}) cells</td>
<td>[59]</td>
</tr>
<tr>
<td></td>
<td>IL-2R(^+)</td>
<td>Reduced T(_{\text{reg}}) cells</td>
<td>[19]</td>
</tr>
<tr>
<td></td>
<td>IL-10(^+)</td>
<td>Reduced T(_{\text{reg}}) cells</td>
<td>[60]</td>
</tr>
<tr>
<td></td>
<td>NOD2(^+)</td>
<td>Impaired innate immunity</td>
<td>[61]</td>
</tr>
<tr>
<td></td>
<td>Msi68(^+)</td>
<td>Impaired TLR signal</td>
<td>[65]</td>
</tr>
<tr>
<td></td>
<td>NF-kB(^+)</td>
<td>Impaired pro-inflammatory signal</td>
<td>[62]</td>
</tr>
<tr>
<td></td>
<td>Ccsl1(^+)</td>
<td>Impaired pro-inflammatory signal</td>
<td>[67]</td>
</tr>
<tr>
<td></td>
<td>Mdr1a(^+)</td>
<td>Reduced iT(_{\text{reg}}) cell differentiation</td>
<td>[68]</td>
</tr>
<tr>
<td></td>
<td>TCR(^+)</td>
<td>Defective adaptive immunity</td>
<td>[60]</td>
</tr>
<tr>
<td></td>
<td>TGF(^+)</td>
<td>Reduced T(_{\text{reg}}) cell</td>
<td>[72]</td>
</tr>
<tr>
<td></td>
<td>JAK3(^+)</td>
<td>Balance of Th1 and Th2</td>
<td>[73]</td>
</tr>
<tr>
<td></td>
<td>Muc2(^+)</td>
<td>ER stress</td>
<td>[74]</td>
</tr>
<tr>
<td></td>
<td>A20(^+)</td>
<td>Impaired Myd88 signal</td>
<td>[75]</td>
</tr>
<tr>
<td></td>
<td>TCR(^+)SOS1(^+)</td>
<td>Increased IFN-(\gamma) and IL-4</td>
<td>[76]</td>
</tr>
<tr>
<td></td>
<td>CD4/TGF(^+)</td>
<td>Increased T(_{\text{reg}}) cell function</td>
<td>[77]</td>
</tr>
<tr>
<td></td>
<td>CD4/MDK1(^+)</td>
<td>Reduced T(_{\text{reg}}) cell</td>
<td>[78]</td>
</tr>
<tr>
<td></td>
<td>CD4/Blimp1(^+)</td>
<td>Increased IL-17</td>
<td>[79]</td>
</tr>
<tr>
<td></td>
<td>TGF(^-/-)</td>
<td>Increased CD8 function</td>
<td>[71]</td>
</tr>
<tr>
<td></td>
<td>STAT4TG</td>
<td>Increased TNF-(\alpha)</td>
<td>[80]</td>
</tr>
<tr>
<td></td>
<td>T(AC)401TG</td>
<td>Thymic dysfunction</td>
<td>[81]</td>
</tr>
<tr>
<td></td>
<td>B(AC)401TG</td>
<td>Increased IFN-(\gamma)</td>
<td>[82]</td>
</tr>
</tbody>
</table>

WJG | www.wjgnet.com
body, recent studies have demonstrated that $T_{reg}$ cells are also highly enriched in the visceral adipose tissue (VAT)\textsuperscript{113}. Interestingly, more than 50% $T_{reg}$ cells of CD4$^+$ T cells in the VAT of 20-week-old mice are found\textsuperscript{113}. Differences in the expressions of IL-10, CCR1, CCR2, CCR4, GATA binding protein 3 (GATA3), and peroxisome proliferator-activated receptor $\gamma$ (PPAR$\gamma$) have been observed between VAT $T_{reg}$ cells and effector $T_{reg}$ cells in lymphoid tissues\textsuperscript{113,114}. Moreover, mice with a $T_{reg}$ cell-specific PPAR$\gamma$ deletion that were fed a high-fat diet exhibited impaired restoration of insulin sensitivity and glucose tolerance following pioglitazone treatment\textsuperscript{113,114}. These findings suggest that VAT $T_{reg}$ cells might be critical mediators of the effects of treatment for lipid metabolism disorders.

**REGULATORY T CELL IN IBD**

**Phenotypes of $T_{reg}$ Cells in IBD**

The phenotype and function of $T_{reg}$ cells in the inflamed mucosa or periphery of patients with IBD or animal models have been described as considerably different from those in peripheral lymphoid organs of healthy controls\textsuperscript{12,115} (Figure 1). For example, patients with IBD exhibit reduced numbers of peripheral $T_{reg}$ cells and increased numbers peripheral Th17 cells\textsuperscript{116}. By contrast, the mRNA expression levels of Foxp3 are elevated in the mucosa of patients with IBD along with elevated levels of IL-17A, IL-1$\beta$, and IL-6 mRNA\textsuperscript{116}. In IBD models, dysfunctional suppressive $T_{reg}$ cell function plays a crucial role in the development of IBD lesions via the upregulation of T-cell specific T-box transcription factor (T-bet), STAT-1, and nuclear factor-$\kappa$B (NF-$\kappa$B)-mediated peripheral $T_{reg}$ cell activation\textsuperscript{86}. Intestinal immune system activation in response to bacterial antigens and pathologic cytokine production by intestinal T cells is induced through various transcription factors or signal molecules, including T-bet, GATA-3, and STATs and plays a critical role in the development of IBD\textsuperscript{72,117-119}. CD is associated with the production of Th1 cytokines such as IFN-$\gamma$ and TNF-$\alpha$ and in an IBD model naive T cells transferred into T cell-deficient mice can be controlled by a coinjection of $T_{reg}$ cells which suppress Th1 effector cell

![Figure 1 Molecular contribution to the pathogenesis of inflammatory bowel disease.](image)

In the lesions of inflammatory bowel disease (IBD), a various immune cells and epithelial cells contribute to the onset or development of the disease. Imbalance between cytokines or abnormal expression of chemokine receptors and adhesion molecules through several transcription factors in immune cells including effector T cell influences the pathogenesis of IBD. Decreased number of $T_{reg}$ cells and abnormal differentiation of $T_{reg}$ cells into effector-like phenotype are observed in the IBD lesions.
functions such as IFN-γ production\textsuperscript{120,121}. Moreover, UC development in humans is associated with Th2 cytokines such as IL-5\textsuperscript{122}.

Recent studies have demonstrated that Foxp3\textsuperscript{+} T\textsubscript{reg} cells express retinoic acid receptor-related orphan receptor gamma t and are thus able to differentiate into Th17 cells, a process that is associated with a decreased suppressive T\textsubscript{reg} cell function in patients with IBD. T\textsubscript{reg} cells were found to suppress colonic inflammation by downregulating Th17 responsiveness via TGF-β in an adoptive transfer mouse model of colitis\textsuperscript{123,124}. Additionally, CCR7 was shown to regulate the intestinal Th1/Th17/T\textsubscript{reg} cell balance during CD-like murine ileitis\textsuperscript{125}. Furthermore, IFN-γ/IL-17 coproducing CD4\textsuperscript{+} T cells which express high levels of T-bet, CD26, and IL-22 resemble the pathogenic Th17 cells that contribute to intestinal inflammation in IBD\textsuperscript{126}. Epithelial-derived IL-18 also regulates both colonic Th17 cell differentiation and T\textsubscript{reg} cell function in the context of IBD-associated intestinal inflammation\textsuperscript{124}.

A recent study described Clostridium bacteria as potent inducers of Foxp3\textsuperscript{+} T\textsubscript{reg} cells in the colonic mucosa\textsuperscript{111}. Additionally, CD4\textsuperscript{+}CD8\textsuperscript{αα} colonic T\textsubscript{reg} cells were reported to produce IL-10 in response to Clostridium bacteria and the frequencies of CD4\textsuperscript{+}CD8\textsuperscript{αα} lymphocytes in the LP lymphocytes and peripheral blood were found to be significantly lower in patients with UC than in healthy controls\textsuperscript{127}. These findings suggest that colonic bacteria-induced CD4\textsuperscript{+}CD8\textsuperscript{αα} T\textsubscript{reg} cells may control or prevent IBD.

**Therapeutic Treg cell-based strategies for IBD**

New and effective therapies involving anti-TNF antibodies have yielded remarkable progress in the field of IBD therapy\textsuperscript{150}. In addition, clinical trial applications are underway for target molecules such as IL-6/IL-6R, IL-12/23, IL-17A/F, IL-13, interferon-gamma-inducible protein 10 (IP10), CCR9, Janus kinase 3 (JAK3), similar to mothers against decapentaplegic (Smad)7/TGF, α4β7/β7, and mucosal vascular addressin cell adhesion molecule (MAdCAM)\textsuperscript{4,5,15,22,24}. Target molecules such as IL-17A/F, IL-13, IP10, JAK3, α4β7/β7, or MAdCAM also represent promising therapeutic strategies for UC\textsuperscript{4,5,15,22,24}.

The Foxp3\textsuperscript{+} T\textsubscript{reg} cell frequency was found to be significantly lower in active patients with UC than in healthy controls\textsuperscript{118,116}. On day 14 after an initial dose of anti-TNFα infusion therapy, patients with IBD exhibited a significant increase in the frequency of circulating T\textsubscript{reg} cells along with two- to three-fold increase in Foxp3 expression, which paralleled a reduction of IBD\textsuperscript{120}. Furthermore, another report demonstrated that anti-TNFα mAb [infliximab (IFX)] therapy yielded a significant and sustained relative increase in peripheral blood T\textsubscript{reg} cells; a change in C-reactive protein levels and durable clinical response was associated with this sustained increase in circulating Foxp3\textsuperscript{+} T\textsubscript{reg} cells\textsuperscript{120}. IFX therapy was also shown to downregulate the mucosal expression of Foxp3 mRNA and protein in patients with UC and CD\textsuperscript{120}.

In patients with active IBD, anti-TNF-α treatment rapidly enhances the frequency of functional Foxp3\textsuperscript{+} T\textsubscript{reg} cells in the blood and potentiates their suppressive function\textsuperscript{120}. In addition, these patients increased apoptosis of local Foxp3\textsuperscript{+} T\textsubscript{reg} cells is observed in the inflamed mucosa when compared with noninflamed control colon tissues, along with a reduced frequency and increased apoptosis of peripheral blood T\textsubscript{reg} cells and elevated caspase activity in the serum\textsuperscript{120}. During anti-TNF-α antibody treatment, a decrease in the apoptosis of T\textsubscript{reg} cells was found to correlate closely with an increase in peripheral T\textsubscript{reg} cell numbers and a decrease of caspase and disease activity\textsuperscript{120}.

CD4\textsuperscript{+}CD25\textsuperscript{+}CD127\textsuperscript{−}CD45RA\textsuperscript{−}Foxp3\textsuperscript{+} T\textsubscript{reg} cells appear to be a promising population from which to expand T\textsubscript{reg} cells for autologous T\textsubscript{reg} cell transfer therapy in patients with CD\textsuperscript{131}. Expanded CD45RA\textsuperscript{−}Foxp3\textsuperscript{+} T\textsubscript{reg} cells carry an epigenetically stable FOXP3 locus and do not convert to a Th17 phenotype in in vitro culture and CD45RA\textsuperscript{−} Foxp3\textsuperscript{+} T\textsubscript{reg} cells from patients with CD were found to home to the human small intestine in a C.B-17 severe combined immune deficiency xenotransplant model\textsuperscript{131}. There remains an unmet need for the development of novel therapies for IBD, as current drug therapies frequently fail to maintain long-term remission and may be complicated by significant side effects. Although cellular therapies are emerging as a potentially attractive many hindrances to successful clinical therapy remain in terms of sufficient cell numbers, cell maintenance, and cell sources.

**CONCLUSION**

Although the precise molecular pathogenesis of IBD remains unclear, recent therapeutic strategies involving antibodies against pathogenic cytokines or chemokines have provided treatment opportunities for many more patients suffering from IBD. Additionally, T\textsubscript{reg} cells may provide a more effective therapy for IBD; therefore the unknown mechanisms with respect to T\textsubscript{reg} cell differentiation, function, and maintenance should be clarified.

**REFERENCES**


Lapp C, Robertson ML, Wickham ME, Sekirov I, Champion OL, Gaynor EC, Finlay BB. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host Microbe 2007; 2: 204 [PMID: 18030708 DOI: 10.1016/j.chom.2007.08.002]


Poussier P, Ting N, Chen J, Bamerjeo D, Julius M. Intestinal inflammation observed in IL-2R-/IL-2 mutant mice is associated with impaired intestinal T lymphopoiesis. Gastroenterology 2000; 118: 880-891 [PMID: 10784587 DOI: 10.1016/S0016-5085(00)70174-0]


February 21, 2016 | Volume 22 | Issue 7 | WJG www.wjgnet.com


Lee JH, Kang SG, Kim CH. Foxp3+ T cells undergo conventional first switch to lymphoid tissue homing receptors in thymus but accelerated second switch to nonlymphoid tissue homing receptors in secondary lymphoid tissues. J Immunol 2007; 178: 301-311 [PMID: 17182567 DOI: 10.4049/jimmunol.178.1.301]


McNamee EN, Masterson JC, Veny M, Collins CB, Jedlicka P,


